Gujarat Themis Biosyn (BOM:506879) ROCE %: 15.31% (As of Mar. 2026)


BOM:506879 Gujarat Themis Biosyn Ltd BOM:506879
72 GF Score
Price ₹395.80
GF Value ₹313.02
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Gujarat Themis Biosyn ROCE %?

Gujarat Themis Biosyn BOM:506879 +0.15% 72 ROCE % is 15.31% as of Mar. 2026. GuruFocus rates BOM:506879 with a GF Score™ of 72/100 and a GF Value™ of ₹313.02 (Modestly Overvalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Gujarat Themis Biosyn's annualized ROCE % for the quarter that ended in Mar. 2026 was 15.31%.

Gujarat Themis Biosyn  (BOM:506879) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Gujarat Themis Biosyn ROCE % Related Terms

Gujarat Themis Biosyn ROCE % Historical Data

* Premium members only.

The historical data trend for Gujarat Themis Biosyn's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gujarat Themis Biosyn ROCE % Chart

Gujarat Themis Biosyn Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 67.24 60.50 44.65 27.14 18.45

Gujarat Themis Biosyn Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.02 17.33 22.17 21.03 15.31
BOM:506879
72GF Score
Gujarat Themis Biosyn Ltd BOM:506879
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gujarat Themis Biosyn ROCE % Calculation

Gujarat Themis Biosyn's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=650.389/( ( (3013.125 - 205.597) + (5034.266 - 791.483) )/ 2 )
=650.389/( (2807.528+4242.783)/ 2 )
=650.389/3525.1555
=18.45 %

Gujarat Themis Biosyn's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=649.7/( ( (0 - 0) + (5034.266 - 791.483) )/ 1 )
=649.7/( ( 0 + 4242.783 )/ 1 )
=649.7/4242.783
=15.31 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 15.31% mean?
Gujarat Themis Biosyn (BOM:506879) has a ROCE % of 15.31% as of Mar. 2026.
Is Gujarat Themis Biosyn's ROCE % too high?
Gujarat Themis Biosyn's current ROCE % is 15.31%. The Drug Manufacturers industry median ROCE % is 7.03. Gujarat Themis Biosyn's value of 15.31% is 117.8% above this industry median. Overall, Gujarat Themis Biosyn has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gujarat Themis Biosyn's ROCE % compare to ZTS and UTHR?
Gujarat Themis Biosyn's ROCE % of 15.31% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. Gujarat Themis Biosyn's value of 15.31% is 117.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.03, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gujarat Themis Biosyn's current ROCE % of 15.31% is 117.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gujarat Themis Biosyn's current ROCE % is 15.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gujarat Themis Biosyn stock overvalued right now?
Based on GuruFocus' analysis, Gujarat Themis Biosyn (BOM:506879) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹313.02, compared to a current price of ₹395.80 — trading 26.4% above its estimated fair value. The current ROCE % is 15.31% and 117.8% above the Drug Manufacturers industry median of 7.03. Gujarat Themis Biosyn's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Gujarat Themis Biosyn (BOM:506879), the current ROCE % is 15.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gujarat Themis Biosyn (BOM:506879) Overvalued in 2026?

Based on GuruFocus' analysis, Gujarat Themis Biosyn stock appears to be overvalued. The current stock price of ₹395.80 is trading 26.4% above its estimated GF Value™ of ₹313.02. GuruFocus considers Gujarat Themis Biosyn to be Modestly Overvalued.

Key valuation signals for BOM:506879:

  • ROCE %: 15.31%
  • GF Value™: ₹313.02 vs. price of ₹395.80 (26.4% above fair value)
  • GF Score™: 72/100 with 5 warning signs
  • Industry Position: 117.8% above the Drug Manufacturers median

No single metric tells the full story. See the BOM:506879 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gujarat Themis Biosyn Business Description

Other Exchanges GUJTHEM:India
Address S.V Road, Themis House, 11/12 Udyog Nagar, Goregaon (West), Mumbai, MH, IND, 400104
Gujarat Themis Biosyn Ltd is engaged in manufacturing, exporting, and selling of bulk drugs on a job-work basis. The company operates in one segment which is pharmaceuticals. Its products include Rifamycin-S, which is an intermediate for Rifampicin for the treatment of tuberculosis (TB), and Lovastatin.
72GF Score

Get the complete analysis for BOM:506879

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹395.80
Price
₹313.02
GF Value